Drugs / BAY2402234
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05061251 | Dec 2021 → Dec 2022 | glioma | University of Texas Southwestern Medical Center | Withdrawn | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT03404726 | Mar 2018 → Jan 2021 | leukemia | Bayer | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAY 2402234 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05061251 ↗ |
| Action | Inhibit | “inhibitor of dihydroorotate dehydrogenase” NCT03404726 ↗ |
| Modality | Small molecule | “small molecule inhibitor” NCT03404726 ↗ |
| Route | Oral | “administered once daily by mouth” NCT03404726 ↗ |